The sensitizing effect of BV6 on recombinant-TNF-a and killer TRAIL allows us to consider it a modern therapeutic tool in combination with conventional drugs in different MM cells [85], as well as in acute myeloid leukemia [86,87], chronic lymphocytic leukemia [88], and some solid tumors [89,90,91]. Here, TNF is linked to Miyoshi myopathy.